|
業務類別
|
Biotechnology |
|
業務概覽
|
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases. |
| 公司地址
| 1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005 |
| 電話號碼
| +1 650 822-5500 |
| 傳真號碼
| +1 650 636-9773 |
| 公司網頁
| https://www.annexonbio.com |
| 員工數量
| 96 |
| Dr. Dean Richard Artis, PhD |
Executive Vice President and Chief Scientific Officer |
-- |
27/04/2026 |
| Ms. Jennifer Lew |
Executive Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 495.82K |
27/04/2026 |
| Dr. Jamie Dananberg, M.D. |
Executive Vice President and Chief Medical Officer |
-- |
27/04/2026 |
| Mr. Ted Yednock,PhD |
Executive Vice President and Chief Innovation Officer |
美元 497.58K |
27/04/2026 |
| Mr. Douglas Love, Esq. |
Director, President and Chief Executive Officer |
美元 670.83K |
27/04/2026 |
| Mr. Michael Overdorf |
Executive Vice President and Chief Business Officer |
-- |
27/04/2026 |
|
|
| Mr. Thomas G. Wiggans |
Chairman of the Board |
17/02/2026 |
| Mr. Muneer A. Satter |
Independent Director |
27/04/2026 |
| Mr. William D. Waddill |
Independent Director |
27/04/2026 |
| Ms. Jung E. Choi |
Independent Director |
27/04/2026 |
| Mr. Douglas Love, Esq. |
Director, President and Chief Executive Officer |
27/04/2026 |
| Dr. William H. Carson, M.D. |
Independent Director |
27/04/2026 |
| Mr. William Jones, Jr |
Independent Director |
27/04/2026 |
| Dr. Bettina M. Cockroft, M.D. |
Independent Director |
27/04/2026 |
|
|
|
|
